ACM
APGE

Aster Capital Management’s Apogee Therapeutics APGE Stock Holding History

Aster Capital Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-99
Closed -$3.7K – 841
2026
Q1 		$3.7K Buy
+99
New +$7.19K ﹤0.01% 706
2025
Q2 		– Sell
-1,050
Closed -$33K – 1020
2025
Q1 		$33K Buy
1,050
+960
+1,067% +$37.1K 0.01% 904
2024
Q4 		$4.08K Buy
+90
New +$4.59K ﹤0.01% 889

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Aster Capital Management's APGE Position: Q2 2026 in Review

Aster Capital Management sold out of Apogee Therapeutics (APGE) in Q2 2026, closing a stake of 99 shares — an estimated $3.7K sold.

Aster Capital Management first reported a position in APGE in Q4 2024 and held it in 3 quarters. The position peaked at $33K in Q1 2025. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Aster Capital Management reported no remaining Apogee Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Aster Capital Management sold 99 Apogee Therapeutics shares in Q2 2026, an estimated $3.7K.
  • Aster Capital Management first reported a position in Apogee Therapeutics in Q4 2024 and held it in 3 quarters.
  • Aster Capital Management's Apogee Therapeutics position peaked at $33K in Q1 2025.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.